Metformin Brillpharma (Metformin Hydrochloride)

Metformin Brillpharma is indicated for conditions related to impaired glucose metabolism.

• Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels.
• Prediabetes (impaired glucose tolerance): helps delay progression to overt diabetes.
• Polycystic ovary syndrome: may improve insulin resistance and menstrual regularity (off‑label use).

• Metformin Hydrochloride acts primarily by inhibiting hepatic gluconeogenesis, thereby decreasing hepatic glucose output. It also reduces glucose absorption in the intestine and enhances peripheral tissue sensitivity to insulin, facilitating greater glucose uptake by muscle and adipose tissue without directly stimulating insulin secretion.

Metformin Brillpharma may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects

• Nausea: transient stomach upset, often early in therapy.
• Diarrhea: loose stools that may improve with continued use.
• Abdominal discomfort: cramping or bloating.
• Metallic taste: brief alteration in taste perception.
• Weight loss: modest reduction in body weight.

Serious or Rare Side Effects

• Lactic acidosis: rare but life‑threatening metabolic disturbance.
• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Vitamin B12 deficiency: may develop with long‑term therapy.
• Hepatic dysfunction: abnormal liver enzymes in susceptible individuals.

When prescribing Metformin Brillpharma, clinicians should consider several safety factors.

• Renal function: assess eGFR before initiation and periodically thereafter.
• Hepatic disease: use with caution in patients with liver impairment.
• Alcohol consumption: avoid excessive intake to reduce lactic acidosis risk.
• Pregnancy and lactation: discuss potential benefits and risks with the healthcare provider.
• Drug interactions: review concomitant medications for possible interactions.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin Brillpharma can interact with other medicines, requiring attention to the interaction severity.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate acute renal failure.
• Cimetidine: can increase metformin plasma concentrations.
• Excessive alcohol: heightens risk of lactic acidosis.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycemia symptoms.
• ACE inhibitors or ARBs: monitor renal function and potassium.
• Diuretics: may affect renal clearance of metformin.
• Other antidiabetic agents: adjust dosing to avoid hypoglycemia.